Navigation Links
Telesso initiates post-market head-to-head peripheral IV catheter study
Date:4/22/2009

SYDNEY, Australia April 22, 2009 Telesso Technologies Limited, a global healthcare company, announced today that Miami Children's hospital is the first site to enroll patients in a head-to-head trial evaluating its FDA-approved guide wire-assisted peripheral IV catheter versus the industry's gold standard device for peripheral IV placement. Telesso is funding the catheter clinical trial with Vascular Pathways, Inc. 
 



"This post-market study represents the advancement of an important innovation in medicine designed to reduce the safety risks and costs traditionally associated with peripheral IV catheter use," said Telesso's CEO Nelson Stacks. "We are encouraged by the interest and positive feedback Telesso has received to date, and we look forward to announcing additional sites shortly with data review in Q2-Q3 of this year."



The trial will enroll approximately 400 pediatric, geriatric and oncology patients at three world-class sites who will be treated with either the novel guide-wire assisted peripheral IV catheter or the current standard of care.

About the Guide Wire-Assisted Peripheral IV Catheter

A peripheral vein is the most common site for insertion of a catheter for short-term diagnostic or therapeutic use. The catheter is placed into the peripheral vein in the arm, below the elbow and is typically passed up inside the vein to a length of 2-3 inches. Telesso's uniquely-designed guide wire-assisted peripheral IV catheter device uses a first-in-class retractable nitinol guide wire system that is believed to enable easier IV access, reduce common safety risks, significantly lessen patient pain and discomfort, and provide cost savings to facilities by lowering administrative costs associated with failed IV starts. Telesso believes this catheter device is the first clinically meaningful advancement in peripheral IV access since automatic needle retraction catheters and addresses sig
'/>"/>

Contact: Jeff Riley
riley@telesso.com
619-309-7661
Cytori Therapeutics
Source:Eurekalert

Page: 1 2

Related medicine news :

1. MAP Pharmaceuticals Acquires Proprietary Drug Particle Formulation Technology From Eiffel/Telesso Technologies Limited
2. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
3. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
4. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
5. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Harbinger Research Initiates Coverage on HearAtLast
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... negative and stressful outcomes for parents who have a ... illness, says a recent study led by a researcher ... are numerous and life-changing and stress levels high, the ... research reported positive outcomes as well, a phenomenon known ... recent issue of the American Journal of Orthopsychiatry ...
(Date:4/24/2014)... 2014 ,Take me out to the ballgame, doesn,t ... chips. The more likely culprits include French fries, soda ... for children who play youth baseball, eating unhealthy food ... problems, according to researchers at Wake Forest Baptist Medical ... of Childhood Obesity , found that high-calorie snacks ...
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... Fibroblasts, cells long thought to be boring and irrelevant, ... with heart disease. , Researcher Dr Milena Furtado, and ... at Monash University, found the heart cell fibroblast is ... for a healthy beating heart. , In research published ... found that cardiac fibroblasts are unique cells due to ...
(Date:4/24/2014)... of prescription opioid overdose deaths was outlined yesterday in ... leaders of agencies in the U.S. Department of Health ... care providers to expand their use of medications to ... a number of misperceptions that have limited access to ... medications can be used in combination with behavior therapies ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Take the bat, leave the candy 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Boring cells could hold the key to heart disease 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4
... The California Veterinary Medical Association (CVMA) warns ... when procedures such as teeth cleaning or therapeutic ... is because special training is necessary and some ... and may require anesthesia. Under California law, only ...
... someday yield therapies to restore sight, experts suggest , , ... plays a major role in two forms of childhood ... researchers. , The discovery of the link between the ... retinitis pigmentosa is important because it pinpoints a new ...
... experts warn , , THURSDAY, March 5 (HealthDay News) -- ... have positive or neutral attitudes toward people who are ... prospective patients, a new study has found. , "Essentially, ... weight bias, and there are negative attitudes toward obese ...
... a national provider of healthcare information technology outsourcing, ... Total Security Program which is designed to offer ... of security services that assess, remediate and monitor ... The Program goes beyond regulated compliance requirements to ...
... Realize New Executive LeadershipKOBE, Japan, March 5 ... leading medical diagnostics instrument manufacturer and laboratory information ... Sysmex Corporate and its subsidiaries in the Americas, ... Kazuya Obe will return to Sysmex Corporate after ...
... headed by Dr. Tom Feasby, Dean of UCalgary,s Faculty ... countries in the number of diagnostic imaging devices, more ... times. The study,s authors say it is critical to ... "This study shows there are important deficiencies in the ...
Cached Medicine News:Health News:Consumers Beware: Unlicensed Care of Animals May Cause Health Problems and Increased Costs 2Health News:Retinal Gene Is Linked to Childhood Blindness 2Health News:Bias Against Obesity Is Found Among Future Dietitians 2Health News:Bias Against Obesity Is Found Among Future Dietitians 3Health News:Phoenix Health Systems Launches Total Security Program for the Healthcare Industry 2Health News:Sysmex Corporation Announces Organizational Changes 2Health News:Lack of strategies to manage MRI wait lists a key reason for excessive wait times 2
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of ... Home Medical Equipment, Inc. ("Progressive") of Clarion, PA ... acquisition were not disclosed. Progressive is a ... range of sleep, mobility, and respiratory products to customers in ...
(Date:1/14/2014)... Jan. 14, 2014 NineSigma , Inc., the ... Innovation Leadership Summit , May 14-16, 2014 at ... Cleveland Ohio . This is ... committed to breakthrough achievements through open innovation. Participants will ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... financial results for the first quarter ended March 31, 2011 ... financial markets. NxStage will also host a conference ... 2011 to discuss its first quarter financial results. To listen ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today that the ... Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) ... neuroendocrine tumors (NET) of pancreatic origin. ... from the everolimus RADIANT (RAD001 In Advanced Neuroendocrine ...
Cached Medicine Technology:NxStage® to Report First Quarter Fiscal 2011 Financial Results 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
... Mesh Self-Forming Plug is a mesh plug ... well as primary inguinal hernias and femoralhernias. ... defect and fills it completely. Premilene Mesh ... of the established Premilene Mesh. The plug ...
... The Celsius Control System provides ... can safely,and rapidly lower patient ... target temperature and,rewarm patients to ... System consists of an endovascular,catheter, ...
... , it maximizes use by allowing ... it, while the third lamp is ... care in mind, it includes universal ... An excellent choice for hospital operating ...
... Perfectly balanced, the patented Orion incorporates ... that illuminates brilliantly. The fully adjustable ... designed to sit low on the brow, ... vision. Two clips on the headband ...
Medicine Products: